Difference between revisions of "Part:BBa K4165151"

 
Line 5: Line 5:
 
Tau binding peptide targeting the PHF seed of Tau
 
Tau binding peptide targeting the PHF seed of Tau
  
−
<!-- Add more about the biology of this part here
 
 
===Usage and Biology===
 
===Usage and Biology===
 +
 +
M4W39 is a peptide with amino acid sequence of DVWMINKKWK, it is designed to inhibit the fibrilization of tau which is one of the main drivers of Alzheimer’s disease and other dementia diseases. PHF* (VQIINK) is the site that derive tau aggregation. M4W39 can bind to PHF* in a mean that can disrupt the interface between each PHF* and consequently reduce the aggregates. Its IC<sub>50</sub> for inhibition of tau aggregates were 2.9 μM.
  
 
<!-- -->
 
<!-- -->
 
<span class='h3bb'>Sequence and Features</span>
 
<span class='h3bb'>Sequence and Features</span>
 
<partinfo>BBa_K4165151 SequenceAndFeatures</partinfo>
 
<partinfo>BBa_K4165151 SequenceAndFeatures</partinfo>
 +
 +
===Dry Lab===
 +
 +
<p style=" font-weight: bold; font-size:14px;"> Modeling </p>
 +
modeled by AlphaFold2, Apptest, ITASSER, best model obtained from AlphaFold2
 +
 +
 +
 +
<html>
 +
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/m4w39.png" style="margin-left:200px;" alt="" width="300" /></p>
 +
</html>
 +
 +
                            Figure 1.: Predicted 3D structure of Synthetic peptide M4W39.
 +
 +
 +
 +
<p style=" font-weight: bold; font-size:13px;"> Table 1: Quality assessment parameters of M4W39 model. </p>
 +
 +
<html>
 +
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/w4m39-qa.png" style="margin-left:75px;" alt="" width="800" /></p>
 +
</html>
 +
 +
 +
===References===
 +
1. Seidler, P. M., Boyer, D. R., Rodriguez, J. A., Sawaya, M. R., Cascio, D., Murray, K., ... & Eisenberg, D. S. (2018). Structure-based inhibitors of tau aggregation. Nature chemistry, 10(2), 170-176.
  
  

Revision as of 18:47, 5 October 2022


M4W39 Peptide

Tau binding peptide targeting the PHF seed of Tau

Usage and Biology

M4W39 is a peptide with amino acid sequence of DVWMINKKWK, it is designed to inhibit the fibrilization of tau which is one of the main drivers of Alzheimer’s disease and other dementia diseases. PHF* (VQIINK) is the site that derive tau aggregation. M4W39 can bind to PHF* in a mean that can disrupt the interface between each PHF* and consequently reduce the aggregates. Its IC50 for inhibition of tau aggregates were 2.9 μM.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]

Dry Lab

Modeling

modeled by AlphaFold2, Apptest, ITASSER, best model obtained from AlphaFold2 


                            Figure 1.: Predicted 3D structure of Synthetic peptide M4W39.


Table 1: Quality assessment parameters of M4W39 model.


References

1. Seidler, P. M., Boyer, D. R., Rodriguez, J. A., Sawaya, M. R., Cascio, D., Murray, K., ... & Eisenberg, D. S. (2018). Structure-based inhibitors of tau aggregation. Nature chemistry, 10(2), 170-176.